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1875-9572/Copyright ª 2016, Taiwan P
NC-ND license (http://creativecommoBackground: Apnea intervals frequently occur in premature infants. Periods of apnea occur
more often with decreases in gestational age. Periods of apnea can cause damage to the in-
fant’s developing brain and other organs. This study was designed to investigate the preventive
effects of caffeine on apnea incidence in higher-risk neonates.
Methods: In this single-center randomized control trial study, premature infants with a birth
weight of 1200 g were eligible for enrollment. Twenty-six infants were randomly assigned
to receive 20 mg/kg caffeine, as the loading dose, which was followed by 5 mg/kg daily as
the maintenance dose until the 10th day of life; these infants were compared with 26 infants
in the control group. Primary outcomes were incidence of apnea, bradycardia, and cyanosis.
Results: Fifty-two infants were enrolled (26 in the caffeine group and 26 in the control group).
The preventive effect of caffeine on apnea was significant in these infants. The relative risk for
incidence of apnea in preterm neonates with a birth weight of <1200 g was 0.250 (95% confi-
dence interval, 0.097e0.647). Only four infants (15.4%) in the caffeine group developed apnea,
compared with 16 (61.5%) in the control group (p Z 0.001).
Conclusion: It seems that preventative effects of caffeine on apnea become apparent by using
the drug in very premature infants.
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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Apnea intervals frequently occur in preterm infants.1,2 The
American Academy of Pediatrics describes apnea as a
noninspiratory period lasting for 20 seconds, together
with bradycardia and/or cyanosis.2,3 Periods of apnea occur
more often with decreases in gestational age.4 Despite the
fact that apnea can occur solely because of the prematurity
of the infant, certain situations, such as hypoxic periods,
metabolic disorders, intracranial pathologies, and in-
fections can also trigger it.1
Long periods of apnea can result in infant cyanosis or
bradycardia, and resuscitation of the neonate is required as
cardiopulmonary arrest occurs.1 Periods of apnea can cause
damage to the infant’s developing brain, and also disrupt the
function of the intestine and other organs.4 Recurrent and
long intervals of apnea can result in respiratory failure,
making intubation and ventilation mandatory.1 Apnea and
hypoxemia cause electroencephalographic abnormalities
and also leukomalacia leading to behavioral and neurological
difficulties.5 After the 1980s, pulse oximetry and heart
monitoring of premature infants were routinely used.5 Pre-
mature infants usually experiencea suddendecrease inblood
oxygen saturation, which is sometimes accompanied with an
apnea period and requires immediate medical support.2
Methylxanthines stimulate breathing efforts and, therefore,
they have long been used for treating apnea of prematu-
rity.1,6,7 They also decrease the need for mechanical venti-
lation and can be useful before extubation.8 Although the
mechanismof action is not yet clearly known, optimization of
the response of chemoreceptors to Partial Pressure of Carbon
Dioxide (pCO2) rise, improvement in the function of respira-
tory muscles, and central nervous system (CNS) stimulation
have been noted.1 Two commonly available forms of meth-
ylxanthines are theophylline and caffeine.5 Compared with
the former, caffeinehasmore certain intestinal absorption, a
wider therapeutic index, and a longer half-life, which makes
it possible to be administered daily.6 Prevention of apnea and
hypoxic intervals avoids the side effects of using oxygen,
intubation, and related complications (Levitt G, Harvey D.
The use of prophylactic caffeine in the prevention of
neonatal apnoeic attacks. Unpublished manuscript.
1988:235e43).3e9 Consequently, several trials have been
conducted to discover a treatment for neonatal
apnea.6,7,10e12 However, only a few have aimed at finding
agents useful for preventing apnea of premature neonates
(Levitt G, Harvey D. The use of prophylactic caffeine in the
prevention of neonatal apnoeic attacks. Unpublished manu-
script. 1988:235e43).5 The hypothesis of the present study
was that the use of prophylactic caffeine would reduce the
incidence of apnea in preterm neonates who weighed
<1200 g. The objectives were to compare: frequency of the
incidence of apnea, bradycardia, and cyanosis; duration of
continuous positive airway pressure (CPAP); need of me-
chanical ventilation; duration of hospitalization; and death
(if occurring) in a double-blinded randomized trial.
2. Materials and methods
This study was a double-blinded, placebo-controlled, ran-
domized clinical trial, which was approved by theInstitutional Review Board at the Isfahan University of
Medical Sciences, Isfahan, Iran. The study sample consisted
of infants admitted to the Neonatal intensive care unit
(NICU) at Alzahra and Shahid Beheshti hospitals in Isfahan-
Iran, between September 2013 and January 2014, who were
born prematurely with a birth weight of 1200 g and had
spontaneous breathing at 24 hours of life. Infants having
major congenital anomalies, asphyxia, congenital cyanotic
heart disease, intrauterine growth retardation, a need for
mandatory ventilation on the 1st day of life, and sepsis in
the 1st week of life were excluded. The preventive impact
of caffeine on the incidence of apnea was studied in two
groups of caffeine (Group C) and placebo (Group P). A 1:1
randomization was performed using a computer-generated
randomization list prepared by an independent statisti-
cian who was not involved in the rest of the investigation. In
the intervention group, caffeine 20 mg/kg (intravenously
(IV)) was administered as the initial dose on the 1st day of
life, and then 5 mg/kg (intravenously) daily was used as the
maintenance dose for the first 10 days of life. The placebo
group received an equivalent volume of normal saline daily
during the first 10 days of life. Caffeine and normal saline
were prepared in similar syringes by a trained nurse who
was blind to the group assignment. A trained nurse
numbered the syringes, and the investigator, who was blind
to the numbering, allocated numbers to infants in sequence
of entry into the study.
The same respiratory management protocol was used for
the treatment of patients studied. If clinical evidence of
respiratory distress and/or reduction of arterial oxygen
saturation by pulse oximetry (SpO2) existed, nasal CPAP was
initiated at a continuous pressure of 5e6 cmH2O at a flow
rate of 8e10 L/min. Short binasal prongs delivered CPAP to
the infants. Settings in both groups were adjusted accord-
ing to arterial blood gases, and clinical parameters and
SpO2 was maintained between 88% and 92%. Surfactant
(Survanta or Curosurf) was administered if the studied ne-
onates needed a fraction of inspired oxygen (FIO2) of >30%
to maintain an SpO2 of >88e92%. The intubation-surfac-
tant-extubation (INSURE) approach was used in both
groups, only as a rescue therapy. We gave a second or third
dose of surfactant if the neonates required an FIO2 of >40%
to maintain the desired saturation.
The impact of caffeine to prevent apnea, bradycardia,
and cyanosis in the first 10 days of life was the primary
outcome in the two groups. Apnea was counted if a pause in
breathing for 20 seconds, together with bradycardia and/
or cyanosis, occurred. Bradycardia was considered to be
present if the heart rate slowed down by at least 20% from
the baseline for 20 seconds. Cyanosis was considered to be
present if the neonate had an SpO2 of <85%. All data were
based on daily neonatal intensive care unit reports and
monitor downloads. The secondary outcomes were: mea-
surements of the duration of CPAP; need to use mandatory
ventilation; incidence of intraventricular hemorrhage
(IVH), patent ductus arteriosus (PDA), and necrotizing
enterocolitis (NEC); and drug side effects (such as tachy-
cardiadan increase in the sinus rate of above 160e180
beats/min13), which was monitored daily. The indication
for intubation and use of mandatory ventilation was
considered as repeated apnea 3 times per hour or a one-
time apnea that needed ventilating with a bag and mask.
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noted. Duration of dependency on oxygen and the inci-
dence of chronic lung disease (CLD; oxygen dependency at
28 days of life)14,15 were noted by long-term follow up.
Owing to ethical issues and safety, if apnea occurred,
caffeine was also administered to the control group infants.
Primary and secondary outcomes were recorded by certi-
fied personnel who were blinded to the infant
randomization.
2.1. Statistical analysis
The sample size of 52 infants was based on the sample size
design for the primary outcome of a previous study (Levitt
G, Harvey D. The use of prophylactic caffeine in the pre-
vention of neonatal apnoeic attacks. Unpublished manu-
script. 1988:235e43). The sample size was adjusted
according to the opinion of a statistical consultant and
based on the following formula: NZðz1þz2Þ
2ð2pð1pÞ
d2
, where Z1
is the 95% confidence interval (CI), which was 1.96; Z2 is the
power of the test, which was 0/80 or 0/84; P is an estimate
of the frequency of incidence of each factor in both groups,
in which 0.5 was considered regarding the variations in
each group; and d is the minimum difference in the inci-
dence of each variable between the two groups, in which a
statistically significant difference of 0.8P was considered.
Data are expressed as means with standard deviations
(continuous variables) or as numbers with percentages
(categorical variables). The characteristics of the study
participants were analyzed using Chi-square test, Fisher’s
exact test, ManneWhitney test, independent t test, or
analysis of variance, as appropriate. All data were analyzed
by SPSS software, version 20.0 (SPSS, Chicago, IL, USA). All
tests for statistical significance were two tailed, with an a-
error of 0.05. The adjusted relative risks (RRs) (with 95%
CIs) for the incidence of apnea, bradycardia, and cyanosis;
need for mechanical ventilation; IVH; PDA; NEC; drug side
effects (tachycardia); CLD; and death were calculated by
logistic regression analysis.
2.2. Ethics statement
Prior to the enrollment, parents of all study participants
were provided with written informed consent forms. This
paper is derived from a residency thesis No. 292152 in
Isfahan University of Medical Sciences. This trial was
registered at IRCT.ir (reference number
IRCT2013110610026N3).
3. Results
Throughout the trial, a total of 114 preterm infants with a
birth weight of 1200 g were assessed for study eligibility.
Fifty-six infants were excluded because of not meeting the
inclusion criteria, their parents’ refusal to participate,
major congenital anomalies, and occurrence of apnea on
the 1st day of life. Fifty-eight neonates were randomized,
and finally 52 infants completed the study (Figure 1). De-
mographic characteristics were similar between the two
groups (Table 1). In the caffeine group, there were 15
(57.7%) males and 11 (42.3%) females. The placebo groupconsisted of 13 (50.0%) males and 13 (50.0%) females. No
statistically significant difference between the two groups
was noted by the Chi-square test (p Z 0.57; Table 1).
The primary outcomes were clearly different between
the two groups. Only four infants (15.4%) in the caffeine
group developed apnea, compared with 16 (61.5%) in the
placebo group (p Z 0.001). In the caffeine group, two
(7.7%) and five (19.2%) of the neonates developed brady-
cardia and cyanosis, respectively, compared with 16 infants
(61.5%) that did not receive caffeine (p < 0.05). The RR
(95% CI) values of developing apnea, bradycardia, and
cyanosis were 0.250 (0.097e0.647), 0.125 (0.032e0.490),
and 0.313 (0.134e0.727), respectively (Table 2). Three in-
fants in the caffeine group developed severe apnea and
needed mechanical ventilation (p Z 0.118). The incidence
of IVH, PDA, and NEC was similar in the two groups:
p Z 0.233, p Z 0.760, and p Z 0.245, respectively. No
medication side effect (tachycardia) was reported in the
neonates (p > 0.99; Table 2). The incidence of CLD showed
a statistically significant difference between the two
groups. Only four infants (15.4%) in the caffeine group
developed CLD, compared with 11 (44.0%) in the placebo
group (p Z 0.025). The RR and 95% CI values of developing
CLD were 0.350 and 0.128e0.954, respectively. Only one
baby died in the caffeine group, while no death was re-
ported in the placebo group (p Z 0.510; Table 2).4. Discussion
In our randomized, double-blind, placebo-controlled trial,
the occurrence of apnea in the caffeine group was clearly
less than that in the control group. A few trials have
tested drugs for preventing apnea of premature neonates.
Bucher and Duc5 and Levitt and Harvey (Levitt G, Harvey
D. The use of prophylactic caffeine in the prevention of
neonatal apnoeic attacks. Unpublished manuscript.
1988:235e43) studied preterm infants that were adminis-
tered caffeine citrate at an initial dose of 20 mg/kg. The
maintenance doses used in Levitt et al’s9 study and Bucher
and Duc’s5 study were 5 mg/kg/d and 10 mg/kg/d,
respectively (Levitt G, Harvey D. The use of prophylactic
caffeine in the prevention of neonatal apnoeic attacks.
Unpublished manuscript. 1988:235e43). Levitt et al9
continued the trial until the postmenstrual age of
32 weeks, while Bucher and Duc5 discontinued the trial
after 96 hours. Bucher and Duc5 reported bradycardia and
hypoxia intervals as primary outcomes, but apnea was not
directly measured. Levitt reported apnea as the initial
result and described it as a noninspiratory period lasting
for at least 20 seconds, along with cyanosis or brady-
cardia. In these trials, no changes were noted in the
primary outcomes between the caffeine and placebo
groups. The occurrence of side effects and need of
mandatory ventilation were also similar (Levitt G, Harvey
D. The use of prophylactic caffeine in the prevention of
neonatal apnoeic attacks. Unpublished manuscript.
1988:235e43).5,9 The prophylactic effect of caffeine in
the present trial is probably because apnea occurrence
was investigated instead of bradycardia and hypoxemia, as
was the case in the Bucher and Duc’s5 trial. It may be
claimed that these incidents are scaled up in the case
Figure 1 Flowchart of the participants.
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motion, and metabolic rate. Moreover, the present clinical
trial was conducted in very high-risk infants (prematureTable 1 Characteristics of the study population and the
continuous variables measured.
Variables Caffeine group
(n Z 26)
Placebo group
(n Z 26)
p
Male 15 (57.7) 13 (50.0) 0.578
Female 11 (42.3) 13 (50.0) 0.536
Gestational age
(wk)
28.73  1.95 28.57  2.06 0.783
Birth weight (g) 966.9  194.14 1007.7  134.02 0.382
Need of CPAP (d) 3.96  3.98 5.96  3.20 0.052
Oxygen dependency
time (d)
14.42  19.08 22.69  23.14 0.166
Time of
hospitalization
(d)
47.19  26.17 41.80  18.25 0.394
Data are presented as n (%) or mean  standard deviation.infants with a birth weight of <1200 g). Davis et al11
studied outcomes of premature infants treated with
either caffeine or placebo until 18e21 months of their
corrected ages. The occurrence rate of apnea was not
noted in this trial, but the need for PDA closure and the
duration of mandatory ventilation were lower in the group
that received prophylactic caffeine.11 Henderson-Smart
and De Paoli et al,1 after reviewing these researches,
reported that methylxanthines did not have a preventive
effect on premature neonate apnea, but concluded with
the recommendation that oncoming trials should measure
apnea-preventing effects of methylxanthines in very high-
risk premature neonates. This study was designed for
higher-risk neonates and also for the investigation of the
preventive effects of caffeine on neonatal apnea. Inci-
dentally, it appears that when infants at higher risk are
studied, the preventive effects of caffeine become
apparent.
The small number of participants in this study was a
limitation, although the results were significant. The results
revealed that the more immature the infant, the greater
the benefit of prophylactic caffeine on the incidence and
severity of apnea. Fifty-two premature neonates were
included in the present study; therefore, our study can be
Table 2 Study outcomes.
Variables Caffeine group
(n Z 26)
Placebo group
(n Z 26)
p RR 95% CI
Apnea 4 (15.4) 16 (61.5) 0.001 0.250 0.097e0.647
Bradycardia 2 (7.7) 16 (61.5) <0.001 0.125 0.032e0.490
Cyanosis 5 (19.2) 16 (61.5) 0.002 0.313 0.134e0.727
Mechanical ventilation 3 (11.5) 0 (0.0) 0.118 Not calculated Not calculated
IVH 6 (23.1) 3 (11.5) 0.233 2.000 0.559e7.156
PDA 7 (26.9) 8 (30.8) 0.760 0.875 0.372e2.060
NEC 0 (0.0) 2 (7.7) 0.245 Not calculated Not calculated
Tachycardia 0 (0.0) 0 (0.0) >0.999 d d
CLD 4 (15.4) 11 (44.0) 0.025 0.350 0.128e0.954
Death 1 (3.8) 0 (0.0) 0.510 Not calculated Not calculated
Data are presented as n (%).
The p values and adjusted RRs, with 95% CIs, for the incidence of apnea, bradycardia, and cyanosis; need for mechanical ventilation;
IVH; PDA; NEC; drug side effect (tachycardia); CLD; and death in the two groups were calculated by logistic regression analysis.
CI Z confidence interval; CLD Z chronic lung disease; IVH Z intraventricular hemorrhage; NEC Z necrotizing enterocolitis;
PDA Z patent ductus arteriosus; RR Z relative risk.
412 A.-M. Armanian et alconsidered as a pilot study, and further studies are war-
ranted to confirm this association.
5. Conclusion
Our study was designed to investigate the preventive ef-
fects of caffeine on neonatal apnea in higher-risk neonates.
It seems that preventative effects of caffeine on apnea
become apparent by using the drug on very premature in-
fants. However, further studies using larger sample sizes
are recommended to investigate the issue.
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